Most innovative cancer drugs facing delays in reaching patients 29 Jan 2020 Despite increasing numbers of cancer drugs being licensed, an analysis has found that highly innovative drugs took longer to reach NHS patients than more conventional treatments. Find out more Show/Hide
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020 The ICR has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck cancer and is calling for an urgent reassessment of the evidence for the drug’s benefit. Find out more Show/Hide
ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy 28 Nov 2019 The Institute of Cancer Research, London, welcomes the approval by NICE of the innovative targeted cancer treatment palbociclib for women with advanced breast cancer who have already received hormone therapy. Find out more Show/Hide
ICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutations 26 Jul 2019
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer 06 Jun 2018
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018
European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer 22 Nov 2017
ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer 16 Nov 2017